Clinical trials
Patient Safety clinical trials
Below are recruiting patient safety clinical trials, each written for real people, not researchers. We’re tracking 1,355 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07484061Recruiting
Drinkable supplement for hair loss in women on weight-loss drugs
This trial tests if a special drinkable supplement can help prevent or reduce hair loss in women who are taking a GLP-1 or GIP receptor agonist (a type of weight-loss or diabetes medication). The study looks for women who have just started this medication or have been on it for less than 3 months.
Madrid, MadridAges 35 years+ - NCT07494305RecruitingPhase 2
Testing a new drug for bipolar depression
This trial tests an investigational drug called LB-102 for people with bipolar I disorder who are currently experiencing a major depressive episode without psychosis. It aims to see if the drug is safe and effective for treating depression symptoms.
Bentonville, ArkansasAges 18–65 - NCT06600022RecruitingPhase 1/Phase 2
Studying SCTB41 for advanced solid tumors
This trial tests a new drug called SCTB41 in people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and if it shrinks tumors.
Guangzhou, GuangdongAges 18 years+ - NCT07147114RecruitingPhase 4
Combined macitentan and dapagliflozin for heart failure with lung high blood pressure
This trial tests whether adding two medications—macitentan and dapagliflozin—together is safe and effective for people with heart failure and a certain type of high blood pressure in the lungs. It might help improve your symptoms and daily function.
BusanAges 19 years+ - NCT07359066RecruitingPhase 1/Phase 2
SPR1020 for advanced solid tumors with DNA repair defects
This trial tests an experimental drug (SPR1020) for people with advanced solid tumors that have not responded to standard treatments, especially those with BRCA or related gene mutations. The drug is taken by mouth and the study aims to find the right dose and see if it helps shrink tumors.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05053802RecruitingPhase 2
Microwave tumor ablation plus immunotherapy for multiple lung cancers
This Phase 2 trial studies whether combining microwave ablation (a procedure to destroy lung tumors) with an immune checkpoint inhibitor can control multiple early lung cancers safely. It also aims to see how well the immune treatment helps after ablation, in people whose cancers have not spread.
Shanghai, Shanghai MunicipalityAges 18–79 - NCT07229742RecruitingPhase 2
Study of SHR-2173 for active lupus nephritis
This trial tests a new medicine called SHR-2173 for people with active lupus nephritis, a kidney inflammation caused by lupus. The goal is to see if it is safe and effective.
Nanjing, JiangsuAges 18–70 - NCT07036172RecruitingPhase 3
Semaglutide vs Wegovy for weight loss in Chinese adults
This trial compares a semaglutide injection to the already-approved weight loss drug Wegovy in Chinese adults with obesity. It aims to see if the new option works just as well to help people lose weight.
BeijingAges 18–75 - NCT05905926Enrolling by invitationPhase 3
Tenapanor safety study for teens with constipation-predominant IBS
This trial checks the safety of tenapanor in children and teens (ages 6 to under 18) with IBS-C. It is only for people who finished a previous related study and agreed to continue follow-up.
Foley, AlabamaAges 6–18 - NCT07262164RecruitingPhase 1
Testing VG2062 for advanced solid tumors
This trial is testing a new drug called VG2062 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how the body processes it.
HebeiAges 18–75 - NCT06539208RecruitingPhase 1/Phase 2
Study of YOLT-201 for transthyretin amyloidosis with nerve or heart damage
This trial tests an experimental gene-editing medicine called YOLT-201 for people with a type of amyloidosis that damages nerves or the heart. It aims to see if one or two doses can safely stop the disease from getting worse.
Beijing, Beijing MunicipalityAges 18–80 - NCT05552937RecruitingPhase 2
Tafasitamab plus lenalidomide for relapsed large B-cell lymphoma
This trial studies whether the combination of tafasitamab and lenalidomide can work better and be safe for people whose large B-cell lymphoma has returned or did not respond. It may help by targeting lymphoma cells and supporting immune activity, while monitoring side effects closely.
Hangzhou, ZhejiangAges 18 years+ - NCT07340424RecruitingEarly Phase 1
Study of 225Ac-TR2205 for triple-negative breast cancer
This trial tests a new radioactive drug called 225Ac-TR2205 for people with triple-negative breast cancer that has spread. The goal is to see if it is safe and tolerable. It may be an option if you have tried at least two other treatments, including one for metastatic disease.
Jinan, ShandongAges 18 years+ - NCT06487078Recruiting
Study of Lorlatinib for untreated ALK-positive lung cancer
This study looks at how well and how safely the drug lorlatinib works in people with a certain type of advanced lung cancer (ALK-positive NSCLC) who have not had treatment for their advanced cancer yet. The goal is to see how effective it is in the real world.
Paris, ParisAges 18 years+ - NCT07233811Recruiting
Same-day discharge after robotic hysterectomy
This trial tests if it's safe and beneficial to go home the same day after robotic hysterectomy, compared to staying overnight. It includes women with both benign conditions and endometrial cancer, regardless of weight or uterus size.
StockholmAges 18–75 - NCT07742215RecruitingPhase 3
Combination treatment for relapsed or refractory multiple myeloma
This trial tests a new drug (BCD-248) combined with daratumumab for people whose multiple myeloma has come back or stopped responding to previous treatments. The goal is to see if this combination can help control the cancer better.
HomyelAges 18 years+ - NCT05687110RecruitingPhase 1
Testing novobiocin for tumors with DNA repair gene changes
This Phase 1 study tests whether novobiocin is safe and finds the best dose for people whose tumors have specific DNA repair gene mutations. It may help if your cancer is hard to treat with standard options, including certain patients who already tried PARP inhibitors.
Duarte, CaliforniaAges 18 years+ - NCT06596681RecruitingEarly Phase 1
Study of GA for hard-to-treat nerve pain
This early-phase trial tests a new treatment called GA for people with hard-to-treat neuropathic pain that hasn't improved with standard therapies. The goal is to see if it is safe and tolerable.
Beijing, Beijing MunicipalityAges 18–65 - NCT07037446Enrolling by invitation
Occlutech leak device for mitral or aortic paravalvular leaks
This registry tracks the safety and effectiveness of a device designed to close leaks around heart valves (mitral or aortic). It may be an option for people who have significant symptoms like heart failure or anemia from these leaks and are not good candidates for surgery.
KatowiceAges 18 years+ - NCT05759923RecruitingPhase 1
Study of OATD-02 for hard-to-treat solid tumors
This early (first-in-human) study tests whether OATD-02 is safe and tolerable, and whether it shows any anti-cancer activity. It is for adults with certain advanced or metastatic cancers that have already been treated with the standard options.
Bydgoszcz, Kuyavian-Pomeranian VoivodeshipAges 18 years+ - NCT06744920RecruitingPhase 3
New drug for generalized myasthenia gravis
This trial tests a new medication (remibrutinib) versus a placebo to see if it helps adults with generalized myasthenia gravis. You may qualify if your symptoms affect multiple parts of your body and you haven't had certain recent treatments.
Phoenix, ArizonaAges 18–85 - NCT07084012RecruitingPhase 2
Stem cell treatment for recent stroke
This trial tests whether a single infusion of umbilical cord stem cells can help people recover from a recent ischemic stroke (stroke caused by a clot). It is for patients who have had their stroke within the last 72 hours and have moderate to severe symptoms.
Beijing, Beijing MunicipalityAges 18–75 - NCT06024746RecruitingPhase 3
Finerenone plus SGLT2i for hospitalized heart failure
This trial tests whether adding two heart medicines together (finerenone and an SGLT2 inhibitor) helps people who are in the hospital for heart failure recover better. It may be an option for you if you are currently hospitalized and your heart stress markers are high.
Fairhope, AlabamaAges 18 years+ - NCT07429721RecruitingEarly Phase 1
Testing QI-019A for multiple myeloma that came back
This trial tests a new drug called QI-019A for people whose multiple myeloma has returned or stopped responding to at least two prior treatments. The goal is to see if it is safe and if it can help control the disease.
Wuhan, HubeiAges 18 years+
Hear when a new Patient Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for patient safety?
- Yes. Clin2 currently lists 1,355 recruiting patient safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a patient safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a patient safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.